Key Highlights
- Shares trading up 13.27% pre-market to $22.20, extending Wednesday's after-hours surge of over 14%
- Move follows news that partner Taiho Oncology's Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival
- The trial evaluated zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung cancer
- The Independent Data Monitoring Committee recommended unblinding the study based on the positive interim analysis
- Partners plan to pursue U.S. regulatory approval for the combination regimen pending discussions with the FDA
- The catalyst builds on a strong week of momentum after the stock reached a new 52-week high near $19.94 on positive Phase 2 feedback for a separate pipeline candidate
Shares Extend Rally on Positive Trial Data
Cullinan Therapeutics (NASDAQ:CGEM) shares are trading up 13.27% in pre-market action Thursday to $22.20, extending Wednesday's after-hours surge of more than 14% after partner Taiho Oncology's global Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival at a planned interim analysis. The trial evaluated the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Cullinan Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Formerly known as Cullinan Oncology, the company rebranded in April 2024 to reflect its strategic expansion beyond oncology into immunology, leveraging its core expertise in T cell engagers, a modality well-established in oncology now being advanced into autoimmune indications such as systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's disease.
Trial Result Marks Key Regulatory Milestone
The study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the zipalertinib-containing arm, with manageable observed safety. Based on these results, the Independent Data Monitoring Committee recommended unblinding the study, and Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics plan to pursue U.S. regulatory approval for the combination regimen in the first-line setting, pending discussions with the FDA. "These topline results give us confidence in the potential for zipalertinib to offer a first-line treatment option for patients with NSCLC with EGFR exon 20 insertion mutations," said Jeffrey Jones, MD, MBA, Chief Medical Officer of Cullinan Therapeutics.
The catalyst builds on a strong week of momentum for Cullinan, which had already reached a new 52-week high near $19.94 on positive Phase 2 feedback for CLN-049 in acute myeloid leukemia, clearing a path toward a registrational Phase 2 study, and reaffirmed Buy ratings from HC Wainwright with a $30 price target, even as the firm trimmed near-term EPS estimates following Cullinan's third-quarter Earnings miss of $0.81 per share loss versus $0.80 expected.
Conclusion
Cullinan Therapeutics' 13.27% pre-market gain reflects investors pricing in the clinical readout as a potentially transformative catalyst for shares already up sharply year-to-date amid broader healthcare sector strength. With regulatory approval discussions with the FDA now anticipated and full trial results expected at an upcoming international medical conference, the stock's next moves will likely hinge on the pace of that regulatory process for zipalertinib's first-line indication.






Please wait processing your request...